A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
MetadataShow full item record
Colorectal cancer is the third most common cancer worldwide. A significant proportion of patients presents with unresectable metastatic disease or develops metachronous metastases following surgical resection of the primary tumor. The prognosis of the disease has improved over the past two decades, with extended multimodality treatment options and the development of increasingly intensified chemotherapy regimens that now typically include targeted biologics. A recent advance in therapy is a treatment regimen composed of three chemotherapeutic agents (i.e., triplet chemotherapy: 5-fluorouracil [5-FU]/leucovorin [LV], oxaliplatin, and irinotecan; FOLFOXIRI) in combination with the vascular endothelial growth factor inhibitor bevacizumab. This regimen has been shown to elicit significantly improved objective response rates and median progression-free survival compared with 5-FU/LV and irinotecan in combination with bevacizumab. However, triplet chemotherapy has been associated with increased rates of chemotherapy-related adverse events, and treatment-emergent adverse events should be properly managed to minimize treatment interruption or discontinuation. We present herein a review of clinical studies evaluating the safety and efficacy of FOLFOXIRI with bevacizumab in metastatic colorectal cancer, and propose a practical guide for the management of adverse events associated with the regimen.
Is part ofTargeted Oncology, 2016, vol. 11, núm. 3, p. 293-308
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by-nc (c) Loupakis et al., 2016
Showing items related by title, author, creator and subject.
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study) Fernandez-Plana, Julen; Pericay, Carles; Quintero, Guillermo; Alonso, Vicente; Salud Salvia, Maria Antonieta; Mendez, Miguel; Salgado, Mercedes; Saigi, Eugeni; Cirera, Luis (BMC, 2014)Background: This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS ...
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliu, Jaume; Safont, M. J.; Salud Salvia, Maria Antonieta; Losa, F.; García-Girón, C.; Bosch, Carlos; Escudero, P.; López, R.; Madroñal, C.; Bolaños, M.; Gil, M.; Llombart, A.; Castro-Carpeño, J.; González-Barón, M. (Nature Publishing GroupCancer Research UK, 2010)BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based ...
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study Garcia-Alfonso, Pilar; Chaves, Manuel; Muñoz, Andrés; Salud Salvia, Maria Antonieta; García-Gonzalez, Maria; Grávalos, Cristina; Massuti, Bartomeu; González-Flores, Encarna; Queralt, Bernardo; López-Ladrón, Amelia; Losa, F.; Gómez, Maria Jose; Oltra, Amparo; Aranda, Enrique (BioMed Central, 2015)Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability ...